Insta
WHO Temporarily Suspends Trials Of Hydroxychloroquine Against COVID-19 Citing Safety Concerns
Swarajya Staff
May 26, 2020, 11:15 AM | Updated 11:15 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
The World Health Organisation (WHO) has suspended all testing activity involving the anti-malarial drug hydroxychloroquine for the treatment of COVID-19 patients citing safety concerns, reports Hindustan Times.
The development was announced by WHO's Director-General Tedros Adhanom Ghebreyesus yesterday (25 May) in an online briefing. He, however, mentioned that the suspension was temporary by nature and that the safety data is being reviewed by the data safety monitoring board.
The concerns were also backed by the head of WHO's emergencies programme Dr Mike Ryan who underscored that the decision to suspend the solidarity trials of hydroxychloroquine has been taken by the executive group of WHO out of "an abundance of caution."
It should be noted that the drug has been touted by the United States (US)' President Donald Trump and several others as a potential treatment for COVID-19 disease. President Trump had gone as far as to assert that he was taking the drug to help prevent the disease.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.